AIA
BIO icon

Avalon Investment & Advisory’s Bio-Rad Laboratories Class A BIO Stock Holding History

Avalon Investment & Advisory’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,969
Closed -$2.56M – 334
2020
Q3 		$2.56M Sell
4,969
-6,875
-58% -$3.48M 0.06% 165
2020
Q2 		$5.35M Sell
11,844
-3,440
-23% -$1.52M 0.12% 127
2020
Q1 		$5.36M Sell
15,284
-1,138
-7% -$418K 0.14% 134
2019
Q4 		$6.08M Buy
16,422
+192
+1% +$67.7K 0.12% 138
2019
Q3 		$5.4M Sell
16,230
-210
-1% -$68.5K 0.12% 137
2019
Q2 		$5.14M Buy
16,440
+5,334
+48% +$1.6M 0.11% 144
2019
Q1 		$3.4M Buy
+11,106
New +$3M 0.08% 170

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Avalon Investment & Advisory's BIO Position: Q4 2020 in Review

Avalon Investment & Advisory sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2020, closing a stake of 4,969 shares — an estimated $2.56M sold.

Avalon Investment & Advisory first reported a position in BIO in Q1 2019 and held it in 7 quarters. The position peaked at $6.08M in Q4 2019. 491 funds tracked by Wall St. Rank hold BIO as of Q4 2020.

  • Avalon Investment & Advisory reported no remaining Bio-Rad Laboratories Class A position as of Q4 2020 after selling out during the quarter.
  • Avalon Investment & Advisory sold 4,969 Bio-Rad Laboratories Class A shares in Q4 2020, an estimated $2.56M.
  • Avalon Investment & Advisory first reported a position in Bio-Rad Laboratories Class A in Q1 2019 and held it in 7 quarters.
  • Avalon Investment & Advisory's Bio-Rad Laboratories Class A position peaked at $6.08M in Q4 2019.
  • 491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2020.

Based on Avalon Investment & Advisory's 13F filing for Q4 2020, filed 8 Feb 2021.